Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUTCH-WAIST semaglutide trial in obesity-related persistent atrial fibrillation
NL-OMON59809Phase 4Active, not recruiting
- Sponsor
- Rijnstate
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Atrial fibrillation (AFib) and obesity comparing Semaglutide with Placebo (2 arms). Primary endpoints: One-year ranked rhythm outcome and Composite binary rhythm failure/safety endpoint. Started Jul 2024; status: active, not recruiting.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)obesity
Beyond the preview
Go deeper on NL-OMON59809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59809.